Scientists use radioactive tracer to follow leukemia Drug's journey through the body
NCT ID NCT07295951
Summary
This early-stage study aims to understand how the body absorbs, breaks down, and eliminates the experimental drug bleximenib in people with acute leukemia. Researchers will give a small, traceable radioactive version of the drug to 10 participants with specific types of advanced leukemia to track its path. The main goal is to learn how the drug moves through and leaves the body, which helps determine safe and effective dosing for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Christie NHS Foundation Trust Christie Hospital
RECRUITINGManchester, M20 4BX, United Kingdom
Conditions
Explore the condition pages connected to this study.